ViGenCell KRX:308080KOSDAQ
바이젠셀 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked0since Sep 11
ViGenCell (바이젠셀) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals 4 quarters of losses Screener
ViGenCell quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 check units | ₩571m | – | −₩2.5bn | −₩2.3bn |
| Q1 2026 | ₩329m | – | −₩2.8bn | −₩2.6bn |
| Q4 2025 derived | ₩14m | -93.7% | −₩6.3bn | −₩6.1bn |
| Q3 2025 | ₩8m | +1500.2% | −₩2.4bn | −₩2.2bn |
| Q2 2025 | ₩1m | -98.9% | −₩5.7bn | −₩5.4bn |
| Q1 2025 | ₩0m | – | −₩2.7bn | −₩2.6bn |
| Q4 2024 derived | ₩223m | – | −₩3.7bn | −₩3.7bn |
| Q3 2024 | ₩1m | – | −₩3.6bn | −₩3.2bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
ViGenCell top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest ViGenCell news Korean headlines
No articles yet.